Advertisement
Collaboration › Details
Ono Pharmaceutical–Numab: antibody cancer drug, 201703– research + option agreem up to CHF258m + royalties for multi-specific antibody
Period | 2017-03-28 | |
Partner, 1st | Ono Pharmaceutical Co., Ltd. (TSE: 4528) | |
Group | Ono Pharmaceutical (Group) | |
Partner, 2nd | Numab Therapeutics AG | |
Group | Numab (Group) | |
Product | antibody cancer drug | |
Product 2 | antibody technology | |
Numab Therapeutics AG. (3/28/17). "Press Release: Numab and Ono Pharmaceutical Co., Ltd. Enter into a Research and Option Agreement". Pfäffikon.
Numab to receive up to CHF 258 million plus tiered royalties on sales
Numab Therapeutics AG (“Numab”) today announced a research and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”) for the identification of a multi-specific antibody candidate for development in immuno-oncology.
Under the agreement, Ono will obtain an option to acquire intellectual property rights to, and exclusive rights to develop and commercialize, the selected lead compound to be generated through this collaboration, which will exploit one of Ono’s novel therapeutic approaches in immuno-oncology. In exchange Numab will receive research funding and up to CHF 258 million in upfront and milestone payments plus tiered single to double digit royalties on sales.
Oliver Middendorp co-CEO of Numab, said: “We are extremely pleased to start our collaboration with Ono, a company with a track record of scientific excellence and innovation, and that most recently made its mark by launching a new era in cancer treatment with the development of the first anti-PD-1 antibody, Nivolumab/Opdivo.”
Hiromu Habashita, Corporate Officer, and Executive Director of Discovery & Research of Ono, said: “We highly value the capabilities of Numab’s multi-specific antibody platform. It is robust, and optimized to reproducibly yield product candidates with outstanding binding properties. We believe it is ideally suited to fuel our immuno-oncology drug discovery and consequently a multi-specific antibody to be generated through this collaboration will provide hope to sufferers of cancer.”
About Numab
Founded in 2011, Numab develops a proprietary pipeline of multi-specific biotherapeutics in immuno-oncology and immunology, and has a number of discovery partnerships with pharmaceutical companies. Numab’s plug-and-play multi-specifics platform allows for a highly rational and reproducible process that rapidly yields promising clinical candidates with new mechanisms of action, superior efficacy and a favorable safety profile. For further information, visit www.numab.com.
About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to create innovative medicines in specific areas. It focuses especially on the oncology and diabetes areas. For more information, please visit the company’s website at http://www.ono.co.jp/eng/index.html.
MEDIA CONTACTS
Numab Therapeutics AG
Oliver Middendorp
CBO & co-CEO
o.middendorp@numab.com
Capricorn One
Hans Herklots
+41 79 598 7149
capricorn1@bluewin.ch
Record changed: 2022-11-19 |
Advertisement
More documents for Ono Pharmaceutical (Group)
- [1] Memo Therapeutics AG. (11/1/22). "Press Release: Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets". Schlieren....
- [2] Neurimmune AG. (1/17/22). "Press Release: Neurimmune Expands Drug Discovery Collaboration with Ono Pharmaceutical in the Field of Neurodegenerative Diseases". Zürich....
- [3] Numab Therapeutics AG. (3/30/20). "Press Release: Numab Therapeutics Expands Immuno-Oncology Research Alliance with Ono Pharmaceutical Co., Ltd.". Wädenswil (Zurich)....
- [4] Neurimmune AG. (9/18/18). "Press Release: Neurimmune Achieves Milestone in Collaboration with Ono Pharmaceutical". Schlieren....
- [5] Neurimmune AG. (11/9/17). "Press Release: Neurimmune Announces Collaboration with Ono Pharmaceutical in Neurodegenerative Diseases Field". Schlieren....
- [6] Numab Therapeutics AG. (3/28/17). "Press Release: Numab and Ono Pharmaceutical Co., Ltd. Enter into a Research and Option Agreement". Pfäffikon....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top